Gastrointestinal Infections News

AbbVie announced a new interactive online resource, MappingHepC.com, that features national and state-level data on hepatitis C screening, diagnosis and treatment, according to a press release.

The C. Diff Foundation, a non-profit patient advocacy group, has declared November as a Clostridium difficile Awareness Month.

Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral therapy, according to a recently published study.

Data from Australia’s annual bio-behavioral surveillance of people who inject drugs attending needle syringe programs between 2015 and 2017 showed a significant increase in hepatitis C treatment uptake and decrease in viremic prevalence, especially among older patients and those with a history of opioid substitution therapy.

ORLANDO, Fla. — Young children with acute diarrhea were more likely to have reduced frequency and duration of stools when they were administered bovine colostrum in combination with standard therapy, according to research presented at the AAP National Conference & Exhibition. Researchers said these results were also observed when children had rotavirus and Escherichia coli infection.

Significant incidents of hepatitis A outbreaks occurred through direct person-to-person transmission among drug users and homeless individuals during 2017, according to a report from the CDC.

Results from a phase 2 study of Lambda for the treatment of hepatitis D showed a decline of HDV RNA in more than half of treated patients, according to a press release from Eiger BioPharmaceuticals.

TARGET PharmaSolutions initiated patient enrollment for an observational study of patients with chronic hepatitis B to gather real-world data and advance the understanding of HBV, according to a press release.

Revision of standard upper limits of normal to age-specific and sex-specific alanine aminotransferase parameters in children with chronic hepatitis B highlighted ALT fluctuations during childhood and indeterminate HBV classification, according to recently published data.

Daklinza with Sovaldi and ribavirin produced similar rates of sustained virologic response among patients with hepatitis C genotypes 2 and 3 as those treated with Epclusa, according to a recently published study.